Objective: To describe the treatment of a case of olmesartan-induced enteropathy in a patient with inflammatory areas widely distributed along the gastrointestinal tract.
Case Summary: A 75-year-old patient presented with a 5-month history of recurrent severe diarrhea, diagnosed as olmesartan-induced enteropathy. A modified regimen of oral enteric-coated budesonide (EC-BUD), in combination with other antidiarrheal and anti-inflammatory therapies, was prescribed. The patient experienced rapid improvement in symptoms and was able to titrate off all enteropathy medications, including budesonide within 4 months after hospital discharge.
Discussion: Olmesartan-induced enteropathy is a recently identified adverse effect of this angiotensin II receptor blocker. Oral budesonide is indicated for use in Crohn's disease to provide topical anti-inflammatory therapy without significant systemic steroid absorption. Budesonide, as enteric-coated oral 3-mg capsules, was chosen as therapy in this patient because of its localized effect and proven efficacy in gastrointestinal inflammatory disorders. The administration technique was modified to target areas of inflammation throughout the gastrointestinal tract.
Conclusions: We postulate that this modified administration of EC-BUD may be an effective therapeutic modality for olmesartan-induced enteropathy. It may likewise be an appropriate adjunct to other conditions involving widespread gastrointestinal inflammation, including eosinophilic gastroenteritis and gastrointestinal graft versus host disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1060028014540608 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.
Case Rep Med
December 2024
Department of Gastroenterology, Gastrocentro Natal, Natal, Rio Grande do Norte, Brazil.
The case involves a 63-year-old hypertensive man, taking antihypertensive medication (olmesartan) for the previous two years, who sought medical attention due to voluminous diarrhea, with several episodes per day and weight loss of 10 kg. He was submitted to a series of diagnostic procedures without elucidation and empirical treatment with unsuccessful outcome. After hospitalization for clinical stabilization and for presenting with duodenal atrophy, obtained by duodenal biopsy associated with negative markers for celiac disease, the patient was diagnosed with suspected olmesartan-induced enteropathy, showing rapid improvement of diarrhea after the drug was withdrawn, with weight regain in 6 months and normalization of the duodenal histological picture after 10 months.
View Article and Find Full Text PDFPathognomonic Features of Olmesartan-Induced Collagenous Sprue Resulting in Severe Small Bowel Malabsorption.
Cureus
October 2024
Gastroenterology, Sutter Santa Rosa Regional Hospital, Santa Rosa, USA.
Collagenous sprue (CS) is a rare autoimmune gastrointestinal disorder characterized by specific histologic changes in the small intestine. It often presents with more severe symptoms and a worse prognosis compared to celiac disease, including significant malabsorption, weight loss, and nutrient deficiencies. Despite treatment with a gluten-free diet, symptom improvement is limited, with only a small fraction of patients responding positively.
View Article and Find Full Text PDF[Sartan-induced enteropathy].
Rev Med Suisse
September 2024
Service de médecine interne, eHnv Hôpital de Saint-Loup, 1318 Pompaples.
Olmesartan-induced enteropathy was first described twelve years ago. Clinically it is characterized by diarrhea, weight loss and malabsorption. Histological analysis may show duodenal villous atrophy and/or epithelial lymphocytosis (duodenal/colic).
View Article and Find Full Text PDFChronic diarrhoea, weight loss and a positive anti-tissue transglutaminase antibody: A case report of olmesartan-induced enteropathy.
BMJ Case Rep
May 2024
Gastroenterology Unit, NHS Lothian, Edinburgh, UK.
Article Synopsis
- * A case study highlights a woman in her 50s who experienced intermittent loose stools and significant weight loss, leading to two slightly elevated anti-tissue transglutaminase (ATTG) antibody tests.
- * After thorough investigations, she was diagnosed with olmesartan-induced enteropathy, which resolved after stopping the medication, emphasizing the need to consider olmesartan when diagnosing SLE and noting the unusual presence of raised ATTG antibodies.
Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report.
Case Rep Gastroenterol
April 2024
Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Article Synopsis
- - Olmesartan, a medication for high blood pressure, can lead to a rare gastrointestinal issue called enteropathy that develops over time, often causing severe malabsorption problems and complications like poor blood flow to organs.
- - A case study describes a 43-year-old woman who experienced severe diarrhea and liver problems after taking olmesartan for two weeks, highlighting the seriousness of this complication.
- - The case underscores the importance for doctors to be vigilant about potential enteropathy and liver issues in patients using olmesartan, as stopping the medication led to quick recovery from diarrhea and liver function normalization.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!